

Asadur Rahman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6784773/publications.pdf>

Version: 2024-02-01

33
papers

770
citations

430442

18
h-index

525886

27
g-index

33
all docs

33
docs citations

33
times ranked

1107
citing authors

#	ARTICLE	IF	CITATIONS
1	Renoprotective Effects of Mangiferin: Pharmacological Advances and Future Perspectives. International Journal of Environmental Research and Public Health, 2022, 19, 1864.	1.2	14
2	Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. Journal of Human Hypertension, 2021, 35, 148-156.	1.0	38
3	Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats. International Journal of Molecular Sciences, 2021, 22, 2069.	1.8	11
4	Effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, on sodium dynamics in hypertensive subtotaly nephrectomized rats. Journal of Pharmacological Sciences, 2021, 146, 98-104.	1.1	1
5	The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. Journal of Pharmacological Sciences, 2020, 142, 124-126.	1.1	10
6	Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 1844-1855.	1.9	10
7	Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Communications Biology, 2020, 3, 724.	2.0	5
8	Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease. Hypertension Research, 2020, 43, 492-499.	1.5	28
9	Association of a Disrupted Dipping Pattern of Blood Pressure with Progression of Renal Injury during the Development of Salt-Dependent Hypertension in Rats. International Journal of Molecular Sciences, 2020, 21, 2248.	1.8	6
10	Interactions between Host PPARs and Gut Microbiota in Health and Disease. International Journal of Molecular Sciences, 2019, 20, 387.	1.8	46
11	Melatonin in chronic kidney disease: a promising chronotherapy targeting the intrarenal renin-angiotensin system. Hypertension Research, 2019, 42, 920-923.	1.5	22
12	PPAR β activation mitigates glucocorticoid receptor-induced excessive lipolysis in adipocytes via homeostatic crosstalk. Journal of Cellular Biochemistry, 2018, 119, 4627-4635.	1.2	17
13	The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. Frontiers in Endocrinology, 2018, 9, 421.	1.5	84
14	Altered Circadian Timing System-Mediated Non-Dipping Pattern of Blood Pressure and Associated Cardiovascular Disorders in Metabolic and Kidney Diseases. International Journal of Molecular Sciences, 2018, 19, 400.	1.8	26
15	A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS ONE, 2018, 13, e0192531.	1.1	60
16	Antiproliferative effects of polyclonal antibody against (pro) renin receptor in pancreatic ductal adenocarcinoma cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-29.	0.0	0
17	Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertension Research, 2017, 40, 535-540.	1.5	33
18	Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 522-525.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Combination therapy of over-the-scope clip and covered metallic stent for refractory multiple esophagobronchial fistulae and stenosis. <i>Digestive Endoscopy</i> , 2017, 29, 393-394.	1.3	2
20	Innovative delivery method using a detachable device to deliver a large polyglycolic acid sheet to a gastric ulcer perforation. <i>Endoscopy</i> , 2017, 49, E165-E167.	1.0	5
21	Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	19
22	Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. <i>Scientific Reports</i> , 2017, 7, 9555.	1.6	26
23	IBMX protects human proximal tubular epithelial cells from hypoxic stress through suppressing hypoxia-inducible factor-1 α expression. <i>Experimental Cell Research</i> , 2017, 358, 343-351.	1.2	7
24	Current Status of Exposed Endoscopic Full-Thickness Resection and Further Development of Non-Exposed Endoscopic Full-Thickness Resection. <i>Digestion</i> , 2017, 95, 6-15.	1.2	19
25	Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. <i>Journal of Hypertension</i> , 2016, 34, 893-906.	0.3	45
26	The Development of Endoscopic Suturing Devices: Challenges in the Treatment of Iatrogenic Perforation and Bleeding. <i>Internal Medicine</i> , 2016, 55, 3075-3076.	0.3	2
27	Novel and effective countertraction using a ring-shaped thread for safer gastric and colorectal endoscopic submucosal dissection. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 735-736.	0.5	4
28	A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. <i>Hypertension Research</i> , 2016, 39, 415-422.	1.5	51
29	Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. <i>Hypertension Research</i> , 2015, 38, 237-243.	1.5	28
30	Role of the renal sympathetic nerve in renal glucose metabolism during the development of type 2 diabetes in rats. <i>Diabetologia</i> , 2015, 58, 2885-2898.	2.9	49
31	High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway. <i>Hypertension Research</i> , 2014, 37, 13-18.	1.5	28
32	Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on accumulation of aliskiren in the kidney. <i>Journal of Hypertension</i> , 2013, 31, 659-660.	0.3	0
33	Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Pharmacological Effects of Mineralocorticoid-Receptor Blockers. <i>Journal of Pharmacological Sciences</i> , 2009, 109, 1-6.	1.1	31